Categories
Entertainment

Kylie Jenner, Timothée Chalamet seashore trip: pictures

Kylie Jenner and Timothée Chalamet’s hot beach photos will leave you glowing

Timothée Chalamet And Kylie Jenner keep their romance hot and steamy.

The Marty Supreme The star and the Kylie Cosmetics founder each shared a glimpse of a wet and wild tropical vacation on what appeared to be the same beach.

In pictures posted to him Instagram On March 30, Timothée enjoyed the sun as he walked shirtless on a deserted beach in black trunks and lounged in the shallow waters of the secluded bay.

Another picture showed the 30-year-old making waves in the sea on a watercraft while a yacht rolled along the horizon in the distance.

Although Timmy didn’t share any snaps of Kylie – who he has been dating since 2023 – she did share some scantily clad pictures of her own from a seaside holiday.

In a March 29th Instagram In her post, the 28-year-old founder wore a black string bikini in the crystal clear water and wrote: “Having the time of my life.”

Categories
Technology

Allbirds is promoting all of its property for $39 million

The wool sneaker brand, which briefly reached a valuation of $4 billion in 2021, has agreed to sell all of its assets and intellectual property rights to American Exchange Group.

The company dissolves. Shares rose 36% in after-hours trading as $39 million is still a premium to the already trading price.

Allbirds has agreed to sell all of its intellectual property and assets to American Exchange Group for $39 million, about a tenth of the $348 million the company raised in its 2021 initial public offering and a fraction of the more than $4 billion valuation the company briefly reached on its first day of trading.

The company plans to completely dissolve after the transaction is completed. The sale, which is subject to shareholder approval, is expected to close in the second quarter of 2026, with net proceeds distributed to shareholders in the third quarter after accounting for settlement costs.

The 💜 of EU technology

The latest rumors from the EU tech scene, a story from our wise old founder Boris and questionable AI art. It’s free in your inbox every week. Register now!

Compounding the murky deal is one detail: Allbirds shares closed at $2.98 on Monday, giving the company a market capitalization of about $24.5 million. The sale price of $39 million was a premium to the stock’s existing inventory.

Shares rose about 36% in after-hours trading on the news, a measure of how far expectations had already fallen. Revenue was down 22% to $161 million in the last twelve months; The company reported negative EBITDA of approximately $75 million.

Allbirds had also closed all full-price stores in the US by February 2026, retaining only two stores in the UK and two outlet locations in the US.

The demise of Allbirds is a familiar cautionary tale about what happens when a brand based on a unique product idea, the Wool Runner, a $95 Merino wool sneaker that Time magazine once called “the most comfortable shoes in the world,” tries to become a lifestyle company.

After its IPO in 2021, Allbirds aggressively expanded into physical retail and new product categories: leggings, jackets, performance running shoes. None of them had any connection to the customer base that purchased the original product. Losses were piling up.

Co-founder Tim Brown later acknowledged that the expansion had cost the company “some of our DNA.”

American Exchange Group (AXNY), which is acquiring the brand, is an 18-year-old private brand management company in the accessories and licensing space. His existing portfolio includes Aerosoles, Jonathan Adler, White Mountain, Ed Hardy and Born, among others.

The Allbirds deal was negotiated by a special committee of independent directors and received unanimous board approval. TD Cowen serves as financial advisor to Allbirds; Holland & Hart is legal counsel.

Categories
Technology

There may be battery expertise that shops greater than 9 occasions extra vitality and is ideal on your units

Battery life is one of the biggest bottlenecks in modern devices, from phones to wearables. Now researchers have developed a new lithium-ion battery design that could dramatically change that without sacrificing durability.

What’s so impressive about this new battery technology?

Researchers at the University of Surrey have developed a new type of lithium-ion battery anode that can store significantly more energy than traditional designs. It builds on existing silicon-carbon battery technology, with the key improvement being the use of silicon.

Although existing silicon-carbon batteries have a much higher energy density than traditional lithium-ion batteries, they have one major disadvantage. The silicon used in the electrodes can store more energy, but it also expands and cracks over time, causing rapid deterioration.

ACS

To solve this problem, the team developed a new structure called the Vertically Integrated Silicon-Carbon Nanotube. It uses a flexible framework of carbon nanotubes coated with silicon, allowing the material to expand and contract without breaking.

The resulting battery can store over 3,500 mAh per gram, compared to around 370 for traditional graphite-based batteries. This is where the statement “up to nine times more energy” comes from.

The new design not only increases capacity but also remains stable over repeated charging cycles, which has long been a major challenge in high-performance batteries.

Why is this new design important?

Silicon-carbon batteries are not exactly new and already offer a major advance over traditional lithium-ion technology. However, major manufacturers such as Apple and Samsung have so far avoided the technology due to reliability concerns.

Repeated expansion and contraction of existing silicon-carbon batteries can cause long-term damage and compromise battery life, performance and safety. For companies shipping millions of devices, this kind of inconsistency is a dealbreaker.

This new design addresses this problem by making the batteries more stable. If it works as expected outside the lab, it could remove one of the biggest hurdles stopping Apple and Samsung from adopting silicon-carbon batteries. This could ultimately lead to smartphones and wearables that last significantly longer without compromising reliability.

Categories
Sport

Saints coach Moore: Sufficient snaps for Kamara and Etienne

Multiple authors

New Orleans Saints coach Kellen Moore says there will be enough snaps for running backs Alvin Kamara and Travis Etienne.

Moore, who spoke to the media at Monday’s NFL league meeting, was asked several questions about how the Saints will handle both running backs this season.

Kamara’s future has been a topic of discussion since the Saints signed Etienne to a four-year contract worth $11.8 million per year on March 13. Etienne, 27, spent five seasons with the Jacksonville Jaguars after they selected him with the 25th pick of the 2021 NFL Draft.

Editor’s Tips

Kamara, who turns 31 on July 25, has one year left on his recently restructured contract, which would pay him up to $11.5 million in salary and bonuses this year.

“I’m really excited about the signing of Travis. Obviously Alvin, we love Alvin. He means a lot to all of us,” Moore said. “Again, this is a whole offseason process. Certainly we feel like, ‘Hey, he’s in this room.’ You can find roles for all of these different types. We will go through the entire offseason process and continue to grow and develop this team.”

Kamara is coming off a season in which he had career lows in rushing yards (471), rushing touchdowns (one), receiving yards (186) and receiving touchdowns (zero) after missing six games due to knee and ankle injuries. He also missed the last three games of the 2024 season due to injury.

When asked about the possibility of Kamara resigning in early March, Moore said he would “not get involved in any of those things” but said no such discussions had taken place with him. He also said that the team will “go through this whole process” regarding Etienne and Kamara playing together.

On Monday, he said he hasn’t had any conversations with Kamara since his free agency, but said yes when asked if they would proceed as if Kamara would be with the team in 2026.

“Well, he’s definitely on the roster and part of the running back room,” Moore said. “We feel like there’s opportunities to manipulate all of these guys and put them in a lot of situations. Look back at our season last year, probably look at almost any NFL season. There’s a lot of running backs playing. Obviously we’re happy we were able to get Travis in free agency, but there’s still a lot of work to be done out there.”

Two of Kamara’s best seasons came when paired with running back Mark Ingram. Both defenders had more than 1,500 yards rushing in 2017, when Kamara was named NFL Offensive Rookie of the Year. Kamara also had 1,592 yards from scrimmage and 18 total touchdowns alongside Ingram in 2018.

Moore said the depth of the running back room is one of his strengths. In addition to Kamara and Etienne, this also includes Devin Neal, Audric Estime, Kendre Miller and the recently signed Ty Chandler.

“There are a lot of different ways to do this,” Moore said. “In our running back room, the way last season went, a lot of these guys have experience, a lot of them have played football. So it’s going to be beneficial to us that we have a couple guys, three or four guys that played meaningful snaps last year, all coming back. And then when you throw in Travis, it’s a great situation for us.”

Categories
Health

Eli Lilly reaches deal to convey AI-developed medication to international market

A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, November 21, 2025.

Mike Blake | Reuters

BEIJING – US pharmaceutical giant Eli Lilly has struck a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.

According to the companies’ announcement on Monday, the deal will see Insilico receive $115 million upfront, with the remainder subject to regulatory and commercial milestones as well as royalties on future sales.

Insilico has developed at least 28 drugs using generative AI tools, almost half of which are already in the clinical stage, Insilico founder and CEO Alex Zhavoronkov told CNBC. The company went public in Hong Kong in December. Its shares are up more than 50% since the start of the year.

“In many ways, Lilly is better than us in some areas of AI,” Zhavoronkov said, pointing out that the US pharmaceutical giant has “a person” who has combined biology, chemistry and automation. He added that as part of the deal, Insilico will join Lilly’s Gateway Labs community for biotech development.

The two companies have been working together since signing a licensing agreement for AI-based software in 2023.

“This collaboration allows us to explore new mechanisms and accelerate the identification of promising therapeutics.” C“Andidates across multiple disease areas,” Andrew Adams, group vice president of Molecule Discovery at Lilly, said in a statement. He called Insilico’s AI-powered discovery “a powerful addition” to Lilly’s clinical development.

Eli Lilly CEO David A. Ricks attended a high-level forum in Beijing earlier this month, just weeks after the company announced plans to invest $3 billion in China over the next decade. The company reported that a little less than 3% of its sales came from China last year.

Weekly analysis and insights from Asia’s largest economy in your inbox
Subscribe now

Insilico develops its AI outside of China, in Canada and the Middle East, but conducts early preclinical drug development in China based on that AI research, Zhavoronkov said. He said that in addition to reducing research time, AI can synthesize molecules faster than those discovered using more traditional methods.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Categories
Entertainment

Omar Gooding informs followers after severe automobile accident

Send fans Omar Gooding I wish him well after he revealed he was in a serious car accident. The actor shared a video from a hospital bed in which he updated about his condition and other details about the incident.

RELATED: Get Up! Omar Gooding and Cam’ron raise eyebrows after comments on social media (PHOTO + VIDEO)

Omar Gooding breaks his silence about his car accident

On Sunday, March 29, Omar Gooding shared a video on Instagram telling his fans that he was in a serious car accident. The footage showed him lying with a neck brace. Omar still kept his sense of humor and made light of the situation, saying he was fine and didn’t need surgery. He even joked that if someone wanted to do him a favor, he could send him a few seatbelt commercials.

“I’m fine, no surgery needed, thank God!” He continued, “I’m going to start doing seat belt commercials, so if anyone wants to send me something, send me seat belt commercials.”

Omar explained in his caption that he was wearing a seatbelt and didn’t break his neck. He actually suffered the Hangman Fracture while catching a few Zs in the backseat of a car on the way to the airport. His doctors said recovery will take about three months, so he will have to postpone his upcoming show dates.

Fans send good wishes to Omar after hospital update

After The Shade Room shared Omar Gooding’s video, fans flooded the comments section with well wishes. Others continued to joke, saying they couldn’t stand him mentioning the clone comment and that they knew it was upsetting the nurses at the hospital.

Instagram user @lillyvcassandra wrote:🙌🏾 Get well soon sir!!!! 💪🏿”

Instagram user @tiajeanee_ wrote: I know his nurses are freaking out in there 😂🩷”

While Instagram users @shegetswhatshewantsscarlett wrote: A simple thank you for your concern, I’m recovering, would be enough😂😂 regarding cloning.”

Then Instagram user @tasha_s_sayless wrote: I’m mad at him for making me laugh at this tragedy 😂😂”

Another Instagram user @the_an0dyne wrote: “He looks just like his brother now.”

While another Instagram user @india_bookie25 wrote: 🙏🏾❤️ get well soon🩷”

Instagram user @kathy_4.0 wrote: Nobody’s trying to clone YOU now bro…maybe! But thank God you’re okay.”

Finally, Instagram user @mildred.williams.92317 wrote: “Speedy recovery 🙏🏽”

Omar thanks fans for their love amid recovery

In another Instagram video, Omar told fans that he appreciated all the love. But he asked his close friends and family to stop calling because although he looks optimistic in his clips, he is in severe pain and can only move his eyes. He said even talking hurts.

“Thank you so much for all the love!!! Now please let me heal. This hurts like hell. But I’m awesome. N****s break their necks everyday B.. I’ll be fine 💪🏾💪🏾💪🏾 I don’t want to block y’all!! I need my sleep!! 😘😘,” Gooding wrote.

RELATED: Tiger Woods Arrested at Scene of Florida Rollover Accident After Police Suspect Drunk Driving (Mugshot)

What do you think, roommates?

Categories
Technology

Europas Prime-Finanzierungsrunden diese Woche (23.–29. März)

Eine Woche, die sich mit Halbleiterphysik, Orbitallogistik, Verteidigungsabfangjägern und Schokolade auf Johannisbrotbasis befasste, verrät Ihnen etwas über die derzeitige Breite Europas und der angrenzenden Hauptstadt Europas.

Der dominierende Faktor ist nicht ein einzelner Sektor, sondern ein einziger Instinkt: die Unterstützung der Infrastrukturschicht, sei es durch Chip-Verbindungen, Satellitenübertragungsfahrzeuge oder die KI, die den Arbeitsabläufen in Unternehmen zugrunde liegt.

Kandou AI – 225 Millionen US-Dollar Serie A | Lausanne, Schweiz

Kandou AI, ein 2011 gegründetes und kürzlich von Kandou Bus umbenanntes Schweizer Halbleiterunternehmen, hat in einer von Maverick Silicon angeführten Serie A mit strategischer Beteiligung von SoftBank, Synopsys, Cadence Design Systems und Alchip Technologies 225 Millionen US-Dollar eingesammelt und das Unternehmen mit 400 Millionen US-Dollar bewertet. Die Kupferverbindungstechnologie des Unternehmens, die auf einer Signalisierungsmethode namens Chord basiert, verdoppelt bis vervierfacht die Bandbreite und halbiert gleichzeitig den Stromverbrauch, was sie als potenzielle Alternative zu den optischen Verbindungen positioniert, von denen allgemein angenommen wird, dass sie die KI-Infrastruktur dominieren.

Air Street Capital – 232 Millionen US-Dollar Fonds III geschlossen | London, Großbritannien

Laut Sifted hat Air Street Capital seinen dritten Fonds mit 232 Millionen US-Dollar geschlossen und ist damit der größte Einzel-GP-Venture-Fonds, der jemals in Europa aufgelegt wurde. Das von Nathan Benaich geführte Londoner Unternehmen unterstützt KI-orientierte Unternehmen in der Anfangsphase und stellt erste Schecks in Höhe von 500.000 bis 15 Millionen US-Dollar aus, mit einer kleinen Zuteilung für Investitionen in der Wachstumsphase von bis zu 25 Millionen US-Dollar.

Müsli – 125 Millionen US-Dollar Serie C | London, Großbritannien

Das 💜 der EU-Technologie

Die neuesten Gerüchte aus der EU-Tech-Szene, eine Geschichte unseres weisen alten Gründers Boris und fragwürdige KI-Kunst. Es liegt jede Woche kostenlos in Ihrem Posteingang. Jetzt anmelden!

Granola, die in London ansässige KI-Meeting-App, hat in einer Serie C unter der Leitung von Danny Rimer bei Index Ventures 125 Millionen US-Dollar eingesammelt und das Unternehmen mit 1,5 Milliarden US-Dollar bewertet, was einer Versechsfachung gegenüber der Bewertung von 250 Millionen US-Dollar vor weniger als einem Jahr entspricht. Die Finanzierungsrunde erhöht die Gesamtfinanzierung auf 192 Millionen US-Dollar und positioniert die Meetingaufzeichnungen von Granola als KI-Infrastruktur für Unternehmen und nicht als einfaches Produktivitätstool.

Ysios Capital InceptionBio – 100-Millionen-Euro-Fonds | Barcelona, ​​Spanien

Ysios Capital, Spaniens größter Life-Science-VC, hat InceptionBio aufgelegt, einen 100-Millionen-Euro-Fonds, der sich ausschließlich dem Aufbau von Biotech-Unternehmen aus Spin-outs spanischer Universitäten und Forschungszentren widmet, mit CDTI als Anker-LP. Der Fonds zielt auf die riskanteste und am häufigsten gemiedene Phase der Biotechnologie ab und wandelt Laborentdeckungen in juristische Personen um, die über genügend Kapital verfügen, um die präklinischen Daten zu erreichen, die institutionelle Anleger anziehen.

Credo Ventures – $88M Fund V Abschluss | Prag, Tschechische Republik

Credo Ventures hat seinen fünften Fonds mit 88 Millionen US-Dollar geschlossen, den bislang größten und einen Schritt nach oben gegenüber dem vierten Fonds mit 75 Millionen Euro, der 2022 geschlossen wurde, und setzt damit seine fünfzehnjährige Strategie fort, den ersten institutionellen Scheck für Gründer aus Mittel- und Osteuropa und seiner Diaspora auszustellen. Das Prager und Krakauer Unternehmen, zu dessen ersten Wetten UiPath und ElevenLabs gehören, wird bei Preseed typische Schecks in Höhe von 1 bis 5 Millionen US-Dollar ausstellen.

360 Capital – 85 Millionen Euro Deeptech-Fonds | Paris, Frankreich

360 Capital, der Paris-Mailand-VC, der mehr als 500 Millionen Euro an Vermögenswerten verwaltet, hat 85 Millionen Euro für ein neues Deep-Tech-Vehikel gesammelt, das von mindestens einem europäischen Verteidigungsminister unterstützt wird, während sich das Unternehmen auf Dual-Use-Technologien an der Schnittstelle von Software, Hardware und nationaler Sicherheit konzentriert. Der Fonds stellt eine klare Verankerung der europäischen Verteidigungsambitionen in einer Deep-Tech-Investitionsstrategie dar, ein Muster, das mittlerweile bei mehreren kontinentalen Fonds zu beobachten ist.

PaperShell – Zuschuss aus dem EU-Innovationsfonds in Höhe von 40,3 Mio. € | Tibro, Schweden

PaperShell, das schwedische Deeptech-Unternehmen, das strukturelle Verbundwerkstoffe aus Kraftpapier und einem aus landwirtschaftlichen Abfällen gewonnenen Biobindemittel herstellt, hat mit der Europäischen Kommission im Rahmen des EU-Innovationsfonds eine Fördervereinbarung unterzeichnet, mit der 40,3 Millionen Euro eines 83-Millionen-Euro-Projekts zur Erweiterung seines Tibro-Werks auf eine Kapazität von 23.000 Tonnen pro Jahr bis 2030 freigeschaltet werden. Das Material, das bereits von der NATO zugelassen ist und an Kunden in den Bereichen Bau, Verteidigung, Elektronik und Transport geliefert wird, wird vom Unternehmen als stärker als Kunststoffe beschrieben und leichter als Aluminium.

PAVE Space – Startkapital im Wert von 40 Millionen US-Dollar | Renens, Schweiz

PAVE Space, ein 2024 gegründetes Schweizer Startup, das aus dem studentischen Raketenprogramm der EPFL hervorgegangen ist, hat in einer der größten Seed-Runden aller Zeiten im europäischen Weltraum unter der Leitung von Visionaries Club und Creandum 40 Millionen US-Dollar gesammelt. Das Unternehmen baut eine Flotte von Orbitaltransferfahrzeugen auf, die Satelliten in weniger als 24 Stunden von ihrer Startumlaufbahn in ihre Arbeitsumlaufbahn befördern sollen, im Gegensatz zu den sechs bis zwölf Monaten, die heute bei elektrischen Bordantrieben üblich sind.

Spitzenlithographie – 40 Millionen US-Dollar, Serie A | Bergen, Norwegen

Lace Lithography, ein norwegisches Startup, das 2023 vom Physiker Bodil Holst gegründet wurde, hat in einer von Atomico geleiteten Serie A, an der auch Microsofts M12 teilnahm, 40 Millionen US-Dollar gesammelt, um eine Chipmusterungstechnologie zu entwickeln, die einen Strahl aus Heliumatomen anstelle von Licht verwendet. Das Unternehmen gibt an, mit seinem Ansatz Strukturen zu ätzen, die bis zu zehnmal kleiner sind als die, die mit der aktuellen Extrem-Ultraviolett-Lithographie erreicht werden können, und positioniert sich damit als potenzieller Herausforderer für ASMLs nahezu Monopolstellung bei fortschrittlichen Lithographiesystemen.

Origin – 30 Millionen US-Dollar Serie A+ | London, Großbritannien

Origin, ein in London ansässiges HR-Tech-Startup, das vom Team hinter Darwin gegründet wurde (2016 von Mercer übernommen), hat in einer von Notion Capital angeführten Serie A+ 30 Millionen US-Dollar eingesammelt, um seine KI-Plattform zu skalieren, die fragmentierte globale Daten zu Leistungen an Arbeitnehmer in einer einzigen Intelligenzschicht konsolidiert. Das Unternehmen zielt auf einen strukturellen blinden Fleck für multinationale Konzerne: Sozialleistungen sind in der Regel der zweitgrößte Kostenfaktor eines Unternehmens nach der Anzahl der Mitarbeiter, doch die ihnen zugrunde liegenden Daten sind über Versicherungspolicen, Maklerberichte und Anbieterportale in Dutzenden von Sprachen verstreut.

JAAQ – Serie A im Wert von 17 Millionen US-Dollar | London, Großbritannien

JAAQ, die in London ansässige Plattform für digitales Engagement im Gesundheitswesen, hat in einer Serie A von Meridian Health Ventures, Fuel Ventures, Bolt Angels und Guinness Ventures 17 Millionen US-Dollar eingesammelt, um Unternehmenspartnerschaften auszubauen und in die Vereinigten Staaten zu expandieren. Das Unternehmen, das von direkten Inhalten zur psychischen Gesundheit von Verbrauchern auf die Einbettung seiner Bibliothek mit mehr als 10.000 klinisch überprüften Videos in die Produkte von Versicherern, Arbeitgebern und Gesundheitsorganisationen umgestiegen ist, deckt nach eigenen Angaben mittlerweile 1,5 Millionen anspruchsberechtigte Leben ab.

Laigo Bio – 17 Mio. € Saatgut | Utrecht, Niederlande

Laigo Bio, ein in Utrecht ansässiges Biotech-Unternehmen, hat den endgültigen Abschluss einer überzeichneten 17-Millionen-Euro-Seed-Runde abgeschlossen, bei der Biovance Capital als neuer Co-Lead neben dem bestehenden Co-Lead Kurma Partners hinzukommt, um seine SureTACs-Plattform voranzutreiben. Anstatt Proteine ​​zu blockieren, führt das Unternehmen die Zerstörung membrangebundener Proteine ​​durch, die jahrzehntelang als nicht behandelbar eingestuft wurden, und zielt auf Krebs und Autoimmunerkrankungen ab, bei denen die herkömmliche Arzneimittelforschung wiederholt gescheitert ist.

Interloom – 16,5 Millionen US-Dollar Saatgut | München, Deutschland

Interloom, das in München ansässige Startup, das ein sogenanntes Kontextdiagramm für Unternehmensentscheidungen erstellt, hat in einer von DN Capital angeführten Seed-Runde unter Beteiligung von Bek Ventures und dem bestehenden Geldgeber Air Street Capital 16,5 Millionen US-Dollar eingesammelt. Das Unternehmen bildet ab, wie operative Entscheidungen tatsächlich in großen Organisationen getroffen werden, und stützt sich dabei auf Millionen realer Fälle statt auf Dokumentationen, um KI-Agenten das institutionelle Wissen zu vermitteln, das erfahrene Mitarbeiter mit sich führen und selten aufschreiben.

Arkadia Space – 14,5 Mio. € | Castellón, Spanien

Arkadia Space, ein spanisches Antriebs-Startup mit Sitz am Flughafen Castellón und das erste spanische Raumfahrtunternehmen, das für den European Innovation Council Accelerator ausgewählt wurde, hat 14,5 Millionen Euro gesammelt, um sein Wasserstoffperoxid-Antriebssystem als ungiftige Alternative zu Hydrazin zu skalieren. Sein DARK-System war das erste Wasserstoffperoxid-Antriebssystem, das in Europa im Orbit geflogen wurde, und startete im März 2025 auf einer SpaceX-Mission.

Epoch Biodesign – 12 Millionen US-Dollar | London, Großbritannien

Epoch Biodesign, ein 2019 gegründetes Londoner Startup, hat 12 Millionen US-Dollar gesammelt, um seine KI-technisch hergestellten Nylon-6,6-Recyclingenzyme vom Pilotmaßstab in den kommerziellen Maßstab zu überführen, wodurch sich die Gesamtfinanzierung auf über 50 Millionen US-Dollar beläuft. Bei diesem Verfahren werden Nylonabfälle, von Leggings über Auto-Airbags bis hin zu Teppichen, wieder in die Monomere zerlegt, aus denen sie hergestellt wurden. Dabei werden mehr als 90 % zurückgewonnen und der Bedarf an Rohöl-Rohstoffen entfällt.

Giraffe360 – 10 Millionen US-Dollar Serie B | London, Großbritannien

Giraffe360, das in London ansässige Proptech-Unternehmen, das 2016 von den Brüdern Mikus und Madars Opelts in Riga gegründet wurde, hat in einer von Cipio Partners angeführten Serie B 10 Millionen US-Dollar gesammelt, um seine KI-Plattform für Immobilienmedien zu erweitern. Das Unternehmen kombiniert eine proprietäre Roboterkamera mit einem KI-Software-Stack, um aus einem einzigen Besuch vor Ort ein vollständiges Immobilien-Medienkit zu erstellen, das HDR-Fotografie, virtuelle Rundgänge, LiDAR-Grundrisse, Videos und soziale Ressourcen umfasst.

Egide – Saatgut im Wert von 8 Mio. € | Paris, Frankreich

Egide, ein in Paris ansässiges Luftverteidigungs-Startup, das 2025 von den ehemaligen MBDA-Ingenieuren Simon Calonne und Florian Audigier gegründet wurde, hat eine 8-Millionen-Euro-Seed-Runde unter der gemeinsamen Leitung von Expeditions, Eurazeo und Heartcore Capital eingeworben. Das Unternehmen entwickelt elektrisch angetriebene Abfangjäger und Mystique, eine hardwareunabhängige Softwareplattform, die KI-gesteuerte Erkennung nutzt, um massenproduzierte Drohnen im Luft-, Boden- und Seebereich abzuwehren.

Theia Insights – Serie A im Wert von 8 Millionen US-Dollar | Cambridge, Großbritannien

Theia Insights, ein in Cambridge ansässiges KI-Unternehmen, das von einem ehemaligen Amazon-Alexa-Forscher gegründet wurde, hat in einer von MiddleGame Ventures angeführten Serie A 8 Millionen US-Dollar gesammelt, wobei Unusual Ventures zurückkehrte, um statische Branchenklassifizierungssysteme durch eine selbstlernende Wirtschaftskarte zu ersetzen. Das Unternehmen modelliert Unternehmen als mehrdimensionale Einheiten, anstatt sie in einen einzigen Sektor zu zwingen, und geht damit auf die grundsätzliche Unzulänglichkeit von Systemen wie SIC und NAICS für moderne, diversifizierte Unternehmen ein.

Zevero – 7 Mio. $ | London, Großbritannien

Zevero, die in London ansässige CO2-Management-Plattform, hat in einer zweiten Runde mit Unterstützung von Spiral Capital, Gazelle Capital und Deep 30 7 Millionen US-Dollar gesammelt und die Gesamtfinanzierung auf 14 Millionen US-Dollar erhöht, da der regulatorische Druck die CO2-Berichterstattung von einer jährlichen Verpflichtung in eine kontinuierliche Dateninfrastrukturanforderung verwandelt. Das Unternehmen hat seinen Kundenstamm verdoppelt und den ARR im Jahresvergleich um 400 % gesteigert und drängt in den asiatisch-pazifischen Raum und Kontinentaleuropa.

Foreverland – 6 Mio. € | Bari, Italien

Foreverland, das italienische Foodtech-Startup hinter Choruba, einer kakaofreien Schokoladenzutat aus mediterranem Johannisbrot, hat in einer neuen Runde mit Unterstützung von CDP Venture Capital, Linfa und Newtree Impact 6 Millionen Euro eingesammelt, was einer Gesamtfinanzierung von 9,4 Millionen Euro entspricht. Das Unternehmen, das in seinem Werk in Apulien jährlich 500 Tonnen produziert und über eine IFS-Food-Zertifizierung verfügt, ist nach eigenen Angaben nun der einzige Hersteller, der eine kakaofreie Bio-Alternative im industriellen Maßstab anbietet.

SOUS – 4 Mio. € Saatgut | Amsterdam, Niederlande

SOUS, ein 2022 gegründetes Amsterdamer Startup, hat in einer von Seed + Speed ​​Ventures angeführten Seed-Runde, an der auch PeakBridge, āltitude und Gekko Capital beteiligt sind, 4 Millionen Euro eingesammelt, um eine KI-Plattform aufzubauen, die die Kundenfindung, Direktbestellung und Kundenbindung für unabhängige Lebensmittel- und Getränkebetreiber übernimmt. Das Unternehmen zielt auf die strukturelle Lücke zwischen der digitalen Infrastruktur, die großen Ketten zur Verfügung steht, und den Tools, die unabhängigen Restaurants zur Verfügung stehen.

Das aussagekräftigste Signal der Woche war vielleicht nicht eine einzelne Erhöhung, sondern die Konvergenz von Raumfahrt, Verteidigung und tiefergehender Materialwissenschaft, die in denselben sieben Tagen erhebliches Kapital anzog. Europäische Investoren warten nicht länger auf die Bestätigung der USA, bevor sie Schecks für harte, geduldige Technologie ausstellen, und diese Geduld könnte genau das sein, was die nächste Welle von Infrastrukturunternehmen erfordert.

Categories
Technology

Meta’s subsequent sensible glasses sound like a boon for individuals who put on glasses

For the billions of people who rely on prescription glasses every day (including me), smart glasses have always been a somewhat uncomfortable conversation. Sure, you can already buy Ray-Ban Meta frames with built-in prescription, but it looks like Meta has something better in store for us.

According to a Bloomberg report, Meta is working on two new AI glasses designed specifically for people who wear glasses, rather than seeing them as an afterthought. The models could be available in rectangular and rounded frame styles. In contrast to current offers, they are sold through conventional eyewear retailers.

Andy Boxall / Digital Trends

Will the new prescription glasses look different?

This could be the first time the Meta and Ray-Ban collaboration aims its Vision-corrected crown directly at primary audiences. However, this is the extent of the information provided by the outlet. There is no information on how the frames might physically differ from current models.

However, if I were to speculate, it might have something to do with the glass casing, thickness and weight of the glasses.

Beyond the hardware, what I think would make the supposed AI glasses truly prescription-friendly is the ability to talk to any optician in the neighborhood and have them work on it. This kind of accessibility could make the glasses truly prescription-friendly.

Phil Nickinson wears both the Ray-Ban Meta Smart-Lasse and Shokz OpenFit earbuds.

Phil Nickinson / Digital Trends

What else do we know about Meta’s upcoming smart glasses?

The Verge has separately labeled FCC listings for the alleged glasses with the internal codenames “Scriber” and “Blazer.” Both are listed as production units, which usually indicates that launch is not far away. One noticeable detail is that Blazer may be taller than Scriber.

Both models should also support the Wi-Fi 6 UNII-4 band, which current Ray-Ban smart glasses lack. This would open the door to faster data transfer and potentially live streaming. However, no display is expected for either model.

What is clear, however, is that Meta sees glasses wearers as the largest untapped market for its data glasses.

Categories
Health

Eli Lilly’s weight problems drug retatrutide passes late-stage diabetes trial

Eli Lilly’s logo appears at the company’s office in San Diego, California, USA on November 21, 2025.

Mike Blake | Reuters

Eli Lilly announced Thursday that its next-generation obesity drug, retatrutide, has passed its first late-stage trial in type 2 diabetes patients, helping them control their blood sugar levels and lose weight.

The drug lowered hemoglobin A1c – an important measure of blood sugar levels – by an average of 1.7% to 2% compared to placebo across different dosages after 40 weeks, meeting the study’s main goal. Patients began the study with HbA1c levels ranging from 7% to 9.5% and were not taking other diabetes medications.

Retatrutide also met the study’s second goal, helping patients on the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, after 40 weeks, studying only patients who continued to take the drug. When all participants were analyzed, including those who stopped treatment, the highest dose of the drug helped patients lose 15.3% of their weight.

Patients with type 2 diabetes have historically had difficulty losing weight, so Lilly is “very excited” that the drug has resulted in both competitive drops in blood sugar levels and significant weight loss, Ken Custer, president of Lilly Cardiometabolic Health, said in an interview.

The company is also “very pleased” with the relatively low discontinuation rate due to side effects, which is as high as 5%, he added.

More CNBC Health coverage

These are the second late-stage results so far on retatruide, which works differently than existing injections and appears to be more effective, at least for weight loss. Lilly is betting big on retatrutide as the next leg of its obesity portfolio after its blockbuster weight-loss injectable Zepbound and its upcoming pill Orforglipron.

But Lilly has not yet filed for approval of the drug for obesity or diabetes. The company expects to announce results from seven additional Phase III trials of the drug by the end of the year.

There are no comparative studies between retatruide and other medicines, making it difficult to directly compare effectiveness.

Still, retatruide’s A1C reduction doesn’t appear to be the largest Lilly has seen in its portfolio: The highest dose of Zepbound lowered the measure by more than 2% after 40 weeks in two separate studies in diabetes patients.

However, Custer said the A1C reduction from retatruide was still “very, very strong” compared to other diabetes drugs that don’t target gut hormones.

He also said it will be important to have options in the area of ​​obesity and diabetes because “not everyone can be helped or satisfied with the same treatment.” The decision about which drug to take will depend on “customization of solutions and patients,” particularly at the beginning of their diabetes treatment, he added.

For example, Custer said patients who want to regulate their blood sugar may benefit from either Zepbound or retatruide. But if they want to lose more weight, the latter might be a better option, he said.

In the two separate diabetes studies, Zepbound helped patients lose slightly less weight than retatruide. In a study called SURPASS-2, the highest dose of Zepbound helped patients lose an average of 13.1% of their weight after 40 weeks. In the other study, SURPASS-1, the highest dose helped patients lose an average of 11% of their weight after 40 weeks.

The safety profile of retatrutide was similar to that of other injectable medications for diabetes and obesity, causing primarily gastrointestinal side effects. Approximately 26.5% of patients receiving the highest dose experienced nausea, while approximately 22.8% and 17.6% experienced diarrhea and vomiting, respectively.

Only a few patients suffered from dysesthesia, an unpleasant nerve sensation.

Retatrutide is called a “triple-G” drug and mimics three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. This appears to have a stronger effect on a person’s appetite and satisfaction with food than other treatments.

Tirzepatide, the active ingredient in Zepbound, mimics GLP-1 and GIP. Novo Nordisk’s semaglutide, the active ingredient in Wegovy, only mimics GLP-1.

As Retatrutide gets closer to market, Novo is trying to catch up with Lilly. In March 2025, Novo said it had agreed to pay up to $2 billion for the rights to an early experimental drug from Chinese pharmaceutical company United Laboratories International.

Novo’s newly acquired drug is a clear potential competitor to retatrutide because it also takes a three-pronged approach to promoting weight loss and regulating blood sugar. However, Novo’s treatment is much earlier in development, meaning it will take several years to reach patients.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Categories
Sport

Switch Rumors, Information: Is Palmer leaving Chelsea for Man United?

March 29, 2026, 4:05 a.m. ET

Chelsea star Cole Palmer is increasingly disillusioned with the club and is ready to consider a move to Manchester United as Manchester City prepares for Real Madrid to move their midfielder Rodri. Stay with us for the latest transfer news and rumors from around the world.

Home page of transfers | Winter qualities for men | Women’s grades

TRENDING RUMORS

Mohamed Salah had a great time at Roma from 2015 to 2017. Photo by Warren Little/Getty Images

Cole Palmer is increasingly disillusioned with Chelsea and ready to consider a move to Manchester United, according to The Sun. The 23-year-old former Manchester City academy midfielder is frustrated by a change in the Blues’ tactics and is reportedly missing playing with him Nicolas Jackson, who is currently on loan to FC Bayern Munich. Should Chelsea fail to qualify for the Champions League, their chances of retaining the England international, who is also the focus of interest at Real Madrid and Bayern despite struggling with groin and toe injuries this season, would further deteriorate.

– Real Madrid are stepping up their efforts to sign the Manchester City midfielder Rodriaccording to TEAMtalk, who add that the Spain international is in favor of leaving the Etihad. Madrid believe he can help address the lack of experience and composure in midfield since the departures of Toni Kroos And Luka Modric. Meanwhile, Man City are interested in extending Rodri’s contract beyond the current term of 2027, but are aware that the 29-year-old wants to return to Spain and will not stand in his way.

Editor’s Tips

2 relatives

– Manchester City wants to sign Newcastle United Sandro Tonali and Nottingham Forest Elliot Anderson in deals that could cost a total of £190m as the Citizens look to rebuild their midfield, TEAMtalk reports. In addition to Real Madrid’s aforementioned interest in Rodri, Bernardo Silva is also expected to leave the Etihad, which has led to City considering signing more midfielders. City also want Newcastle’s full-back Tino Livramentoand they are ready to offer the players to reach an agreement with them James Trafford, Rico Lewis, Issa Kaboré And Juma Bah of interest to the magpies.

– International central defender Alessandro Bastoni wants to move to Barcelona in the summer, as Marca reports. Although formal negotiations have not yet taken place, the Blaugrana have assessed the 26-year-old and Inter are open to negotiations. However, Barcelona could find it difficult to match Inter’s transfer valuation of around €70 million, so they have other names on their shortlist, including the Tottenham Hotspur pair Micky van de Ven And Luka Vuskovicwho is on loan to Hamburg.

– Inter Miami is taking the possibility of a signing seriously Casemiro after the midfielder confirmed he will leave Manchester United at the end of the season, says Fabrizio Romano. Negotiations have already begun between the 34-year-old’s camp and the MLS club in the hope of reaching a financial agreement. Casemiro is keen to join Miami as the prospect of playing alongside him excites him Lionel Messi. But clubs from Saudi Arabia and Europe are also interested in the Brazilian international.

Expert opinion

play

1:53

Could Liverpool sign Kvaratskhelia or Olise to replace Salah?

Craig Burley discusses who Liverpool could sign to replace Mohamed Salah.

OTHER RUMORS

– Arsenal are in talks to sign Club Brugge and the German U21 striker Nicolò Tresoldi. (Christian Falk)

– Barcelona is one of the clubs keeping a close eye on the Hoffenheim striker Noble Asllani. (Florian Plettenberg)

– Real Madrid and Paris Saint-Germain are among the clubs keen to sign the outgoing Liverpool winger Mohamed Salah in summer. (Football Insider)

– Madrid have a clause that would allow them to re-sign the Osasuna striker Victor Munoz for 8 million euros. (Brand)

– And the club still plans to trigger its €9 million clause to re-sign the attacking midfielder Nico Paz from Como. (AS)

Everything from ESPN. Everything in one place.

Watch your favorite events on the newly improved ESPN app. Learn more about which plan is right for you. Register now

– Manchester United continues to follow Bayern Munich’s development Alphonso Davies as they look for a left-back ahead of the summer transfer window. (Football Insider)

– Borussia Dortmund is Jadon Sanchois the most likely destination as the winger prepares to leave Manchester United permanently on a free transfer this summer after spending this season on loan at Aston Villa. (Football Insider)

– Liverpool are ahead of Arsenal in their efforts to sign the Newcastle United winger Anthony Gordon. (Football Insider)

– Internazionale could compete with AC Milan for Lazio’s centre-back Crazy Mario. The Nerazzurri are also interested in Club Brugge Joel Ordonez, Udinese Oumar Solet and Sassuolo Tarik Muharemovic. (Gazzetta dello Sport)

– RB Leipzig wants to keep Yan Diomande But they are preparing for big offers and will demand €100 million or more for the winger. (Philip Hinze)

– Roma could bet on the Sassuolo midfielder Ishmael Kone If Manu Kone joins International. (Gazzetta dello Sport)

– Sunderland has no intention of renting Brian Brobbey Aston Villa is one of several Premier League clubs interested in the striker. (Football Insider)

– Chelsea and Liverpool are paying close attention to the OH Leuven centre-back Roggerio Nyakossi, which is also monitored by Everton, West Ham United, Fulham and Crystal Palace. (Sun)

– Roma, AC Milan and Internazionale are monitoring the Venezia midfielder Issa Doumbia. (Nicolo Schira)

– Bayer Leverkusen, Eintracht Frankfurt and Borussia Dortmund have gathered information on Karlsruher forward Louey Ben FarhatNice and FC Salzburg are also in the race for the 19-year-old. (Florian Plettenberg)